FCGR2B

From Wikipedia, the free encyclopedia
FCGR2B
Protein FCGR2B PDB 1fcg.png
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesFCGR2B, CD32, CD32B, FCG2, FCGR2, IGFR2, Fc fragment of IgG receptor IIb, FcRII-c, FCGR2C
External IDsOMIM: 604590 MGI: 95499 HomoloGene: 2974 GeneCards: FCGR2B
Orthologs
SpeciesHumanMouse
Entrez

2213

14130

Ensembl

ENSG00000072694

ENSMUSG00000026656

UniProt

P31994
P31995

P08101

RefSeq (mRNA)

NM_001002273
NM_001002274
NM_001002275
NM_001190828
NM_004001

NM_001077189
NM_010187

RefSeq (protein)

NP_001070657
NP_034317

Location (UCSC)Chr 1: 161.66 – 161.68 MbChr 1: 170.96 – 170.98 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Fc fragment of IgG receptor IIb (coded by FCGR2B gene) is a low affinity inhibitory receptor for the Fc region of immunoglobulin gamma (IgG). FCGR2B participates in the phagocytosis of immune complexes and in the regulation of antibody production by B lymphocytes.[5]

Structure[]

There are two major forms of FCGR2B existing (FCGR2B1 and FCGR2B2) and they are created by mRNA splicing mechanism, which results in the inclusion (FCGR2B1) or exclusion (FCGR2B2) of the C1 exon sequence. The presence of the C1 exon sequence (in FCGR2B1) results in tethering to the membrane of B cells, whereas its absence (in FCGR2B2) allows fast internalization of the receptor in myeloid cells. Both forms contain the Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) in their cytoplasmic regions. The extracellular domains are 95% identical to the domains of FCGR2A and almost completely identical to the (the other members of CD32 family).[6]

Expression[]

FCGR2B1 is highly expressed by B cells, and its mRNA has also been identified at lower levels on monocytes. FCGR2B2 is highly expressed on basophils and at low levels on monocytes. Cytokine regulation of the expression is positive in the case of IL-10 and IL-6 and negative in the case of TNF-α, C5a and IFN-γ.[6]

Function[]

The receptor inhibits the functions of activating FcγRs, such as phagocytosis and pro-inflammatory cytokine release, mainly by clustering of FCGR2B with different activating FCGR receptors or with the BCR by immune complexes.[7][6]

The phosphorylated ITIM of FcγRIIB recruits the inositol phosphatases SHIP1 and SHIP2, which inhibit the Ras activation, downregulate MAPK activity and reduce PLCγ function and lead to decreased activation of PKC. Inhibition of the MAP kinase pathway, together with the anti-apoptotic kinase Akt can negatively affect proliferation and survival of the cells.[6]

FCGR2B regulates B cell activation by increasing the BCR activation threshold and suppressing B cell mediated antigen presentation to T cells through the ITIM-dependent inhibitory mechanism.[7] Ligation of FCGR2B on B cells downregulates antibody production, prevents the membrane organization of BCR and CD19 and promotes apoptosis. Co-ligation of FCGR2B on dendritic cells inhibits maturation and blocks cell activation.[6] The negative regulatory role of the FCGRIIB molecule is not limited to BCR-induced B-cell activation, but is also functional on other B-cell activation pathways mediated by CD40 and IL-4.[8]

FCGR2B expression on follicular dendritic cells (FDCs) is important for capturing the antigen-containing immune complexes which are essential for the germinal centre response.[7]

FCGR2B is present on non-leukocyte cells including airway smooth muscle and liver sinusoidal endothelial cells, where small immune complexes are internalized inhibiting the pro-inflammatory signalling.[6]

Autoimmunity[]

FCGR2B is one of the genes thought to influence susceptibility to several autoimmune diseases in humans. Its decreased function is associated with systemic lupus erythematosus, rheumatoid arthritis, Goodpasture's disease, multiple sclerosis and others.[7]

FCGR2B may be a target for monoclonal antibody therapy for autoimmune diseases as well as malignancies.[7][9][10]

See also[]

  • CD32

References[]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000072694 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000026656 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ "FCGR2B Fc fragment of IgG receptor IIb [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2019-06-14.
  6. ^ a b c d e f Anania JC, Chenoweth AM, Wines BD, Hogarth PM (2019-03-19). "The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease". Frontiers in Immunology. 10: 464. doi:10.3389/fimmu.2019.00464. PMC 6433993. PMID 30941127.
  7. ^ a b c d e Smith, Kenneth G. C.; Clatworthy, Menna R. (2010-08-06). "Erratum: FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications". Nature Reviews Immunology. 10 (9): 674. doi:10.1038/nri2821. ISSN 1474-1733.
  8. ^ Horejs-Hoeck J, Hren A, Mudde GC, Woisetschläger M (July 2005). "Inhibition of immunoglobulin E synthesis through Fc gammaRII (CD32) by a mechanism independent of B-cell receptor co-cross-linking". Immunology. 115 (3): 407–15. doi:10.1111/j.1365-2567.2005.02162.x. PMC 1782155. PMID 15946258.
  9. ^ Rankin CT, Veri MC, Gorlatov S, Tuaillon N, Burke S, Huang L, et al. (October 2006). "CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma". Blood. 108 (7): 2384–91. doi:10.1182/blood-2006-05-020602. PMID 16757681.
  10. ^ Zhou P, Comenzo RL, Olshen AB, Bonvini E, Koenig S, Maslak PG, et al. (April 2008). "CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy". Blood. 111 (7): 3403–6. doi:10.1182/blood-2007-11-125526. PMC 2275009. PMID 18216299.

Further reading[]

External links[]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from ""